Navigation Links
Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
Date:3/10/2011

WAYLAND, Mass., March 10, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease. This Phase I award provides Avaxia with approximately $145,000 in research and development funds. If early results are promising, the Company could receive an additional $1 million in Phase II funding.

"We are delighted to have been awarded this grant from the NIH in recognition of the potential of our novel approach to the treatment of celiac disease," said Barbara S. Fox, Ph.D., Avaxia's founder and CEO. "This NIH support provides the funding we need to advance the development of our anti-gluten antibody into pre-clinical models of celiac disease, which is a serious lifelong inherited autoimmune condition, affecting more than 2 million children and adults in the U.S. alone."

About Celiac Disease. Celiac disease is an inherited, autoimmune disease in which the lining of the small intestine is damaged from eating gluten and other proteins found in wheat, barley, rye, and possibly oats.  Celiac disease is also known as celiac sprue, nontropical sprue, and gluten-sensitive enteropathy.  The disease can develop at any point in life, from infancy to late adulthood.  The symptoms of celiac disease can vary significantly from person to person with the most common being abdominal bloating and pain, chronic diarrhea, vomiting, constipation and weight loss.  There is no medication available to treat the disease.  Patients must follow a lifelong gluten-free diet in an attempt to avoid symptoms.  More than 2 million people in the United States have the disease, or about 1 in 133 people.  

About Avaxia Biologics, Inc.:  Avaxia Biologics (www.avaxiabiologics.com) is an early stage company using its proprietary platform to develop orally-delivered antibody therapeutics to treat gastrointestinal disease. The antibodies are designed to address both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Avaxia's unique platform technology is supporting the rapid development of products for inflammatory bowel disease, acute radiation sickness, oral mucositis, celiac disease, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
3. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler
4. DSM Biologics Reports a New Record Achievement with DSMs Proprietary XD® Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
5. MiMedx Completes Acquisition of Surgical Biologics
6. MiMedx Announces Agreement to Acquire Surgical Biologics
7. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
8. Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis
9. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
10. Reportlinker Adds Quality for Biologics
11. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... October – December 2016 Revenues amounted to SEK 0.3 ... Result after tax amounted to SEK -16.3 (-6.5) million, corresponding ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... amounted to SEK -39.5 (-29.5) million Result after tax amounted ...
(Date:2/24/2017)... Ind. , Feb. 24, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the Cowen ... at the Boston Marriott Copley Place on Tuesday, March ... A live webcast of the presentation can be ... archived for replay following the conference via Zimmer Biomet,s ...
(Date:2/24/2017)... 24, 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to a ... internet on Tuesday, March 14, 2017 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
Breaking Medicine Technology:
(Date:2/27/2017)... RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... disorder, but concern for women who become dependent on opioid painkillers has fallen short. ... female patients, compared to a 237% increase in fatal overdoses in male populations.(1) , ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Orange County ... a chronic inflammatory gum condition that occurs when the bacteria in plaque infect the ... referred to as a scaling and root planing or SRP, and can include surgical ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – ... disclosed that despite scientific studies, the Center for Disease Control ( CDC ) and ... . Kenneth B. Liegner, M.D. has compiled into a single volume a compelling ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):